Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
WHS | Ann: Removal from Official List at close 29/06/20 | 29/06/12 | 0 | 919 | |||
|
|||||||
WHS | Ann: Suspension from Official Quotation cob 22/06 | 22/06/12 | 0 | 648 | |||
|
|||||||
WHS | Ann: WHS - Date for removal from ASX Official Lis | 08/06/12 | 0 | 713 | |||
|
|||||||
WHS | Ann: WHS - Proposed Marketing of Properties | 01/06/12 | 0 | 695 | |||
|
|||||||
WHS | News: Warehouse Q3 sales rise, to exit ASX | 11/05/12 | 0 | 595 | |||
|
|||||||
WHS | Ann: WHS - Third Quarter Sales Update | 11/05/12 | 0 | 621 | |||
|
|||||||
WHS | Ann: Half Year Report 2012 Booklet | 19/04/12 | 0 | 561 | |||
|
|||||||
WHS | Ann: Appendix 3Y - Change of Director's Inter | 17/04/12 | 0 | 428 | |||
|
See All Discussions